SMITH & NEPHEW
PLC
Further to the announcements made on
2 November 2023 and 28 March 2024, Smith+Nephew (LSE: SN, NYSE:
SNN), the global medical technology business, announces that following the end of
her employment, Anne-Françoise
Nesmes will be treated in accordance with the 2023
Remuneration Policy (the Policy) and her contract of employment
following the end of her employment on 1 May 2024.
As Anne-Françoise provided the Board with
significant advance notice of her intention to step down, has
evidenced dedication to her role and supported the transition to
John Rogers as incoming Chief Financial Officer, the Remuneration
Committee has exercised its discretion to treat Anne-Françoise as a Good Leaver for
the purposes of unvested PSP awards for 2021, 2022 and
2023.
Anne-Francoise will remain
subject to post-employment shareholding
requirements as set out in the Policy.
Full details will be disclosed in
the Directors' Remuneration Report for the relevant
year.
Enquiries
Investors / Analysts
Katharine Rycroft
Smith+Nephew
|
+44 (0) 1923 477433
|
Media
Charles Reynolds
Smith+Nephew
|
+44 (0) 1923 477314
|
Susan Gilchrist / Ayesha Bharmal
Brunswick
|
+44 (0) 20 7404 5959
|
About Smith+Nephew
Smith+Nephew is a portfolio medical
technology business focused on the repair, regeneration and
replacement of soft and hard tissue. We exist to restore people's
bodies and their self-belief by using technology to take the limits
off living. We call this purpose 'Life Unlimited'. Our 18,000
employees deliver this mission every day, making a difference to
patients' lives through the excellence of our product portfolio,
and the invention and application of new technologies
across our three global business units of Orthopaedics, Sports
Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now
operate in more than 100 countries, and generated annual sales of
$5.5 billion in 2023. Smith+Nephew is a constituent of the FTSE100
(LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used
to refer to Smith & Nephew plc and its consolidated
subsidiaries, unless the context requires otherwise.
For more information about
Smith+Nephew, please visit
www.smith-nephew.com
and follow us on X,
LinkedIn,
Instagram
or Facebook.
Forward-looking
Statements
This document may contain forward-looking statements that may
or may not prove accurate. For example, statements regarding
expected revenue growth and trading profit margins, market trends
and our product pipeline are forward-looking statements. Phrases
such as "aim", "plan", "intend", "anticipate", "well-placed",
"believe", "estimate", "expect", "target", "consider" and similar
expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown
risks, uncertainties and other important factors that could cause
actual results to differ materially from what is expressed or
implied by the statements. For Smith+Nephew, these factors include:
conflicts in Europe and the Middle East, economic and financial
conditions in the markets we serve, especially those affecting
healthcare providers, payers and customers; price levels for
established and innovative medical devices; developments in medical
technology; regulatory approvals, reimbursement decisions or other
government actions; product defects or recalls or other problems
with quality management systems or failure to comply with related
regulations; litigation relating to patent or other claims; legal
and financial compliance risks and related investigative, remedial
or enforcement actions; disruption to our supply chain or
operations or those of our suppliers; competition for qualified
personnel; strategic actions, including acquisitions and disposals,
our success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions
or other changes we make in our business plans or organisation to
adapt to market developments; relationships with healthcare
professionals; reliance on information technology and
cybersecurity; disruptions due to natural disasters, weather and
climate change related events; changes in customer and other
stakeholder sustainability expectations; changes in taxation
regulations; effects of foreign exchange volatility; and numerous
other matters that affect us or our markets, including those of a
political, economic, business, competitive or reputational nature.
Please refer to the documents that Smith+Nephew has filed with the
U.S. Securities and Exchange Commission under the U.S. Securities
Exchange Act of 1934, as amended, including Smith+Nephew's most
recent annual report on Form 20-F, which is available on the SEC's
website at www. sec.gov, for a discussion of certain of these
factors. Any forward-looking statement is based on information
available to Smith+Nephew as of the date of the statement. All
written or oral forward-looking statements attributable to
Smith+Nephew are qualified by this caution. Smith+Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in
Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew.
Certain marks registered in US Patent and Trademark
Office.